0 results for 'Sullivan & Cromwell LLP'
What's Behind the Drop in Corporate Fraud Indictments?
The Justice Department's Corporate Fraud Task Force record is a long litany of achievements punctuated by disappointment and controversy. From case records and statistics, as well as interviews with prosecutors, task force members and defense lawyers, The American Lawyer derived a detailed portrait of corporate fraud prosecutions over the last five years. Perhaps the most curious of the findings is the precipitous decline in major corporate fraud indictments since the re-election of President Bush.Cite as: MBIA Inc., et al v. BN AMRO Bank, N.V. 601475/09, NYLJ 1202477729572, at *1 (App. Div., 1st , January 11, 2011)Before: Peter Tom, J.P.; Angela M. Mazza
Getting Fired: Don't Deal With the In-House Counsel and Deal With It Publicly?
Heaven forbid, IF you get fired, don't talk with the in-house counsel and deal with it in a public manner? Uh oh, that's not what an in-house lawyer wants to hear ...Icahn Blasts ImClone Management
In the wake of a judge's ruling that stripped ImClone Systems of key exclusive patent rights, the biotech's biggest rival wasted little time taking advantage of the situation. After the market closed Tuesday, biotech giant Amgen Inc. said it had licensed the same technology to which ImClone lost its exclusive rights. Meanwhile, in what could lead to a full-blown power struggle, newly elected ImClone director Carl Icahn blasted management for the patent loss and for ImClone's "sorry record" in general.Class Certification Overturned in Enron Shareholder Suit
Plaintiffs lawyer Bill Lerach says that Enron shareholders will ask the Supreme Court to review a March 19 opinion from the 5th U.S. Circuit Court of Appeals that put the brakes on the trial in Mark Newby, et al. v. Enron Corp., which was set to begin on April 16 in U.S. District Judge Melinda Harmon's Houston court.Icahn's Influence Could Dictate ImClone's Decision to Appeal Patent Ruling
Carl Icahn isn't getting his way, at least not yet. ImClone Systems responded to its most famous shareholder's latest attacks by giving him a board seat but keeping Chairman David Kies, despite Icahn's continued public thrashing of him. One indication of Icahn's influence could come in the legal battle over a key patent behind ImClone's sole marketed product, cancer fighter Erbitux. If ImClone reverses course and drops its appeal of the patent case, it would be a concession to one of Icahn's public demands.Cite as: Glacken v. The Incorporated Village Of Freeport, 09-4832, NYLJ 1202473146755, at *1 (Ed NY, Decided October 06, 2010)District Judge Denis R. Hurley
Revenue, Profit, Cash: Managing Law Firms for Success
Brought to you by Juris Ledger
Download Now
Law Firm Operational Considerations for the Corporate Transparency Act
Brought to you by Wolters Kluwer
Download Now
The Ultimate Guide to Remote Legal Work
Brought to you by Filevine
Download Now
Practical Guidance Journal: Protecting Work Product in a Generative AI World
Brought to you by LexisNexis®
Download Now